Essex Woodlands has opened a new office in Shanghai, China, to focus on healthcare investments in pharmaceuticals, medical technology, services and information technology.
Using its new office, Essex Woodlands will assist Chinese entrepreneurs to construct companies in all sectors of the Chinese healthcare industry.
Shanghai office co-managing director David Yang said, "Private equity investments in healthcare in China are increasing steadily, healthcare mergers and acquisitions are increasing, and healthcare IPOs are raising more capital in China than in the US today."
Shanghai office co-managing director Scott Barry said, "The opening of an office in Shanghai is a strategic decision to increase our growth and presence in this region."
The Shanghai office working in collaboration with the Essex Woodlands investment teams in the New York, Palo Alto, Houston and London offices, will supply surplus resources to support investments in China.
Essex Woodlands, in the past, had also established China Cord Blood, a cord blood banking operator, and a manufacturer of cardiovascular stents, Microport Scientific, in China.